Innate Pharma has been granted a patent for methods to treat cancer using anti-NKG2A antibodies. The patent details a specific antibody composition and therapeutic regimen, including administration guidelines, aimed at inhibiting the activity of NKG2A to enhance treatment efficacy. GlobalData’s report on Innate Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Innate Pharma, Personalized cancer vaccines was a key innovation area identified from patents. Innate Pharma's grant share as of July 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer treatment using anti-nkg2a antibodies
The granted patent US12037392B2 outlines a method for treating cancer using an anti-NKG2A antibody that specifically binds to and neutralizes the inhibitory activity of the NKG2A receptor. The claims detail that the antibody consists of a heavy chain and a light chain with specific sequences (SEQ ID NO: 3 and SEQ ID NO: 7, respectively) and is designed to compete with HLA-E for binding to NKG2A. The treatment regimen involves administering the antibody intravenously to the patient at a dosage ranging from 4 to 10 mg/kg body weight, with a recommended frequency of twice per month. The method allows for various administration cycles, including at least four doses, and specifies that the antibody can be given as a loading dose followed by maintenance doses.
The patent further specifies that the method is applicable to individuals with different types of cancer, including hematological tumors and solid tumors. Notably, it mentions specific cancers such as lung cancer and head and neck squamous cell carcinoma (HNSCC), with additional details on the types of HNSCC that can be treated, including oropharyngeal tumors, larynx tumors, and tumors of the oral cavity or hypopharynx. The claims emphasize the flexibility in dosing and administration schedules, allowing for tailored treatment approaches based on the patient's condition and response to therapy.
To know more about GlobalData’s detailed insights on Innate Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
